Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial

Background and objective Sugammadex, a modified γ-cyclodextrin, is a selective relaxant-binding agent designed to reverse the effects of the steroidal neuromuscular blocking agents rocuronium or vecuronium. This study compared the efficacy of sugammadex and neostigmine for reversal of neuromuscular blockade induced by rocuronium for facilitating elective surgery. Methods This randomised, multicentre, parallel-group trial included 98 adult patients. Patients received intravenous propofol for induction followed by sevoflurane maintenance anaesthesia. Neuromuscular blockade was monitored using acceleromyography and a train-of-four (TOF) mode of stimulation. Patients were randomly allocated to receive sugammadex 2.0 mg kg−1 or neostigmine 50 μg kg−1 (with glycopyrrolate 10 μg kg−1) at reappearance of the second response of the TOF (mean 16% twitch height of first response) after the last dose of rocuronium. Safety was evaluated by assessing adverse events, laboratory variables and vital signs. Results Time to recovery of the TOF ratio of 0.9 after sugammadex compared with neostigmine was significantly shorter (P < 0.0001), being 1.5 versus 18.6 min (geometric means). Predictability of response was greater with sugammadex than neostigmine: with 98% of sugammadex patients versus 11% of neostigmine patients recovering to a TOF ratio of 0.9 within 5 min. There were no clinical events related to residual neuromuscular blockade or reoccurrence of blockade. Serious adverse events were observed in two sugammadex-treated patients and in three neostigmine-treated patients, respectively, but none were considered related to study drugs. Conclusion Sugammadex achieved significantly faster recovery of neuromuscular function after rocuronium to a TOF ratio of 0.9 compared with neostigmine (Clinicaltrials.gov identifier: NCT00451217).

[1]  K. Khuenl-Brady,et al.  Sugammadex Provides Faster Reversal of Vecuronium-Induced Neuromuscular Blockade Compared with Neostigmine: A Multicenter, Randomized, Controlled Trial , 2010, Anesthesia and analgesia.

[2]  J. Scholz,et al.  Reversal of Neuromuscular Blockade by Sugammadex after Continuous Infusion of Rocuronium in Patients Randomized to Sevoflurane or Propofol Maintenance Anesthesia , 2009, Anesthesiology.

[3]  K. Candiotti,et al.  Reversal of Profound Neuromuscular Block by Sugammadex Administered Three Minutes after Rocuronium: A Comparison with Spontaneous Recovery from Succinylcholine , 2009, Anesthesiology.

[4]  R. Soto,et al.  Reversal of Profound Rocuronium-induced Blockade with Sugammadex: A Randomized Comparison with Neostigmine , 2008, Anesthesiology.

[5]  M. Eikermann,et al.  Reversal of Profound, High-dose Rocuronium–induced Neuromuscular Blockade by Sugammadex at Two Different Time Points: An International, Multicenter, Randomized, Dose-finding, Safety Assessor–blinded, Phase II Trial , 2008, Anesthesiology.

[6]  C. Meistelman,et al.  Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. , 2008, British journal of anaesthesia.

[7]  L. Skovgaard,et al.  Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision , 2007, Acta anaesthesiologica Scandinavica.

[8]  J. Scholz,et al.  Sugammadex (2.0 mg/kg) significantly faster reverses shallow rocuronium-induced neuromuscular blockade compared with neostigmine (50 μg/kg): 9AP7-10 , 2007 .

[9]  J. Proost,et al.  Early Reversal of Profound Rocuronium-induced Neuromuscular Blockade by Sugammadex in a Randomized Multicenter Study: Efficacy, Safety, and Pharmacokinetics , 2007, Anesthesiology.

[10]  M. Struys,et al.  Reversal of Rocuronium-Induced Neuromuscular Block with the Novel Drug Sugammadex Is Equally Effective Under Maintenance Anesthesia with Propofol or Sevoflurane , 2007, Anesthesia and analgesia.

[11]  P. Hans,et al.  Effective Reversal of Moderate Rocuronium- or Vecuronium-induced Neuromuscular Block with Sugammadex, a Selective Relaxant Binding Agent , 2007, Anesthesiology.

[12]  J. Stensballe,et al.  Reversal of Rocuronium-induced Neuromuscular Block by the Selective Relaxant Binding Agent Sugammadex: A Dose-finding and Safety Study , 2006, Anesthesiology.

[13]  M. Giovannelli,et al.  Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. , 2006, British journal of anaesthesia.

[14]  J. Cyriac,et al.  Acceleromyography vs. electromyography: an ipsilateral comparison of the indirectly evoked neuromuscular response to train‐of‐four stimulation , 2005, Acta anaesthesiologica Scandinavica.

[15]  A. Kopman,et al.  Antagonism of profound cisatracurium and rocuronium block: the role of objective assessment of neuromuscular function. , 2005, Journal of clinical anesthesia.

[16]  K. Kim,et al.  Tactile Assessment for the Reversibility of Rocuronium-Induced Neuromuscular Blockade During Propofol or Sevoflurane Anesthesia , 2004, Anesthesia and analgesia.

[17]  F. Alla,et al.  Can Acceleromyography Detect Low Levels of Residual Paralysis?: A Probability Approach to Detect a Mechanomyographic Train-of-four Ratio of 0.9 , 2004, Anesthesiology.

[18]  T. Heier,et al.  The Influence of Mild Hypothermia on the Pharmacokinetics and Time Course of Action of Neostigmine in Anesthetized Volunteers , 2002, Anesthesiology.

[19]  Mark Bradley,et al.  A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. , 2002, Angewandte Chemie.

[20]  R. Mirakhur,et al.  Neostigmine antagonism of rocuronium block during anesthesia with sevoflurance, isoflurane or propofol , 2001, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[21]  R. Mirakhur,et al.  Dosage of neostigmine for reversal of rocuronium block from two levels of spontaneous recovery , 1999, Anaesthesia.

[22]  T. Fuchs-Buder,et al.  Omitting antagonism of neuromuscular block: effect on postoperative nausea and vomiting and risk of residual paralysis. A systematic review. , 1999, British journal of anaesthesia.

[23]  D. Bevan,et al.  Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children. , 1999, Anesthesia and analgesia.

[24]  H. Mowafi,et al.  Dose-response relationships for neostigmine antagonism of rocuronium-induced neuromuscular block in children and adults. , 1996, British journal of anaesthesia.

[25]  L. Skovgaard,et al.  Good Clinical Research Practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents , 1996, Acta anaesthesiologica Scandinavica.

[26]  M. Naguib,et al.  Dose‐Response Relationships for Edrophonium and Neostigmine Antagonism of Rocuronium Bromide (ORG 9426)‐induced Neuromuscular Blockade , 1993, Anesthesiology.

[27]  R. Bartkowski.  Incomplete reversal of pancuronium neuromuscular blockade by neostigmine, pyridostigmine, and edrophonium. , 1987, Anesthesia and analgesia.

[28]  M. Salem,et al.  Comparison between glycopyrrolate and atropine in a mixture with neostigmine for reversal of neuromuscular blockade. Studies in patients following open heart surgery. , 1985, British Journal of Anaesthesia.

[29]  C. J. Jones,et al.  Effects of intravenous administration of glycopyrrolate and atropine in anaesthetised patients , 1981, Anaesthesia.